Abstract:PD-(L)1 inhibitors have provided new treatment approaches for patients with NSCLC; however, resistance to PD-(L)1 inhibitors or low PD-L1 expression may limit clinical benefit. Tislelizumab, a monoclonal antibody with high affinity and specificity for PD-1, was recently approved in China for the treatment of previously treated classical Hodgkin lymphoma. Tislelizumab was engineered to minimize binding to FcɣR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti- PD-1 therapy. Preliminary reports from this study (NCT04068519) showed that tislelizumab monotherapy was generally well tolerated and demonstrated antitumor activity in Chinese patients with advanced solid tumors. We now present data from patients with NSCLC. This multi-arm, open-label, nonrandomized phase 1/2 study evaluated safety/tolerability, antitumor activity, and survival in patients with histologically/cytologically confirmed advanced solid tumors treated with tislelizumab. Eligible patients progressed on, or were intolerant to, their last standard antitumor treatment and were anti-PD-(L)1 therapy treatment-naïve. Patients received intravenous tislelizumab 200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity. Patients were considered PD-L1-positive if ≥10% of their tumor cells had PD-L1 membrane staining at any intensity using the VENTANA PD-L1 (SP263) assay. Antitumor response was assessed by RECIST v1.1, overall survival (OS) was estimated by Kaplan-Meier analysis, and safety/tolerability was examined by monitoring adverse events (AEs). As of 01 December 2018, 56 patients with NSCLC (nonsquamous, n=31 [55%]; squamous, n=25 [45%]) were enrolled. Forty patients (71%) were male, 53 (95%) had metastatic disease, and 23 (41%) had never smoked; one patient each had an EGFR mutation or ALK rearrangement. Patients were heavily pretreated, with 16 patients (29%) receiving ≥3 lines of prior systemic therapy. The most common treatment-related AEs (TRAEs) were increased AST (n=14; 25%), increased ALT (n=13; 23%), and rash (n=8; 14%). Increased AST (n=3; 5%) and increased ALT (n=2; 4%) were the only grade ≥3 TRAEs occurring in ≥2 patients. Immune-related AEs (irAE) were reported in 12 patients (21%) and were generally of low severity, including 1 patient with grade 2 pneumonitis; 4 patients (7%) experienced a grade ≥3 irAE. The objective response rate (ORR) was 18% (95% CI: 8.9, 30.4), with an ORR of 17% (95% CI: 4.7, 37.4) and 19% (95% CI: 7.5, 37.5) in patients who were PD-L1-positive (n=24) and PD-L1-negative (n=31), respectively. With a median follow-up of 14.6 months (95% CI: 12.0, 15.6), median OS was not reached in patients with NSCLC. Updated data with a follow-up of ≥2 years will be presented, including OS. Tislelizumab was generally well tolerated and demonstrated antitumor activity in NSCLC patients regardless of PD-L1 expression status. Tislelizumab is being evaluated as a single agent or with chemotherapy in phase 3 studies in NSCLC patients (NCT03358875, NCT03594747, and NCT03663205).

TS01.03 Efficacy and Safety Data from a Phase 1/2 Trial of Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

137P Tislelizumab Combined with Chemotherapy As Neoadjuvant Therapy for Stage IIIA-IIIB(N2) Potentially Resectable Squamous Non-Small-cell Lung Cancer (TACT)

P17.02 RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo Vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

P2.04-29 Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Tislelizumab, an Investigational Anti-Pd-1 Antibody, Combined with Chemotherapy As First-Line Treatment for Lung Cancer in Chinese Patients.

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

OA03.04 Tislelizumab Plus Chemotherapy Vs Chemotherapy Alone As First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

Preliminary Results With Tislelizumab, An Investigational Anti-Pd-1 Antibody, In Chinese Patients With Nasopharyngeal Cancer (Npc).

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)

A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab, an Anti-Pd-1 Antibody, Versus Docetaxel in Patients with Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen.

P1.04-36 Tislelizumab Combined with Chemotherapy As First-Line Treatment in Chinese Patients with Advanced Lung Cancer

66P Tislelizumab plus chemotherapy as first-line treatment for lung cancer in Chinese patients

Phase II trial of safety and efficacy of tislelizumab plus chemotherapy in stage II-IV non small cell lung cancer (LungMark).

Tislelizumab For The Treatment Of Classical Hodgkin'S Lymphoma

Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).

Safety And Efficacy Of Long-Term Exposure (Lte) To Tislelizumab In Chinese Patients With Advanced Solid Tumours

A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients

Safety and Efficacy of Tislelizumab Plus Chemotherapy As Preoperative Treatment in Potentially Resectable Locally Advanced Non-Small-cell Lung Cancer Patients.

Effect of Human Hydrosalpinx Fluid on in Vitro Mouse Embryogenesis.